Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Super-cold container firm va-Q-tec expands to meet COVID-19 vaccine demand

Published 11/24/2020, 07:11 AM
Updated 11/24/2020, 07:15 AM
© Reuters. FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Wuerzburg

By Ilona Wissenbach

FRANKFURT (Reuters) - Cold-storage specialist va-Q-tec is significantly expanding its fleet of 2,500 rental containers to meet growing demand to transport COVID-19 vaccines that need to be kept as low as -70 degrees Celsius (-94°F), its chief executive said.

The German company is in talks with all the major pharmaceutical manufacturers of COVID-19 vaccines, CEO Joachim Kuhn told Reuters in an interview.

Kuhn said the company would "significantly expand" its fleet of rental containers in the coming year. He did not specify how many extra containers were planned, though said it would not be to the extent of doubling the fleet.

Va-Q-tec is among a handful of high-end packaging providers who have found themselves in high demand as drugmakers and logistics firms prepares to transport such shots around the world. Its shares have risen by 230% this year, valuing the company at around $690 million.

The company's turnover has increased by 30% annually over the past 10 years. "We expect this growth to continue in a similar form," said the CEO, adding that global vaccine distribution might take several years.

"We are carefully increasing the number. With the market growing by more than 10% per year, we are not afraid that we will be left sitting on empty containers after corona."

The Würzburg-based company completed a 25 million Swiss franc ($27.4 million) bond issue on Monday to help fund its expansion plans.

It manufactures "passive" containers, which use dry ice to keep the contents at ultra-cold temperatures for up to five or six days, as opposed to "active" containers that also use electric motors for cooling.

The vaccine candidate developed by Pfizer (NYSE:PFE) and BioNTech, which uses mRNA technology, needs to be kept at about -70 degrees Celsius, colder than the offerings from Moderna (NASDAQ:MRNA) Inc and AstraZeneca (NASDAQ:AZN) PLC.

Kuhn said va-Q-tec had contracts with the world's 20 largest airlines and major freight-forwarders. He said intercontinental transport with cargo flights was expected to be less of a problem than last-mile distribution on the road, given there was experience in transporting super-cold goods by air.

© Reuters. FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Wuerzburg

"To meet the demand for dry ice is not a big problem in our latitudes with sufficient regional production," Kuhn said. "It will be a challenge in countries that do not have this infrastructure in Africa, Latin America or Russia."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.